NASDAQ: APRE
Aprea Therapeutics Inc Stock Ownership - Who owns Aprea Therapeutics?

Insider buying vs selling

Have Aprea Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Oren GiladPresidentCEO2026-01-3028,100$0.89
$25.01kBuy
John P. HamillSrVPCFOPrin Fin Acct Ofcr2026-01-305,700$0.89
$5.07kBuy
Marc DueyDirector2025-12-1021,459$1.17
$25.00kBuy
John P. HamillSrVPCFOPrin Fin Acct Ofcr2025-12-105,000$1.17
$5.83kBuy

1 of 1

APRE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when APRE insiders and whales buy or sell their stock.

APRE Shareholders

What type of owners hold Aprea Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Tryant LLC226.12%28,000,000$16.74MInsider
Thomas Banks108.14%13,391,146$8.01MInsider
Frank J. Hall38.62%4,781,889$2.86MInsider
David West Wilson23.62%2,924,726$1.75MInsider
Heidi A. Patterson21.71%2,688,221$1.61MInsider
Kdev Investments Ab16.09%1,992,586$1.19MInsider
Michael Reynolds15.99%1,980,040$1.18MInsider
Redmile Group LLC14.28%1,768,718$1.06MInsider
Aigh Capital Management LLC8.20%1,015,541$607.29kInstitution
Oren Gilad3.20%395,695$236.63kInsider

1 of 3

APRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APRE3.63%96.37%Net Buying
PBM1.67%98.33%
MTVA0.21%99.79%
BOLT2.98%97.02%Net Buying
AEON5.90%94.10%

Aprea Therapeutics Stock Ownership FAQ

Who owns Aprea Therapeutics?

Aprea Therapeutics (NASDAQ: APRE) is owned by 18.12% institutional shareholders, 480.58% Aprea Therapeutics insiders, and 0.00% retail investors. Tryant LLC is the largest individual Aprea Therapeutics shareholder, owning 28.00M shares representing 226.12% of the company. Tryant LLC's Aprea Therapeutics shares are currently valued at $16.77M.

If you're new to stock investing, here's how to buy Aprea Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.